BUENA, N.J. , May 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2018 . First Quarter 2018 Highlights The Company adopted ASC 606: Revenue from

BUENA, N.J. , May 07, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, initially announced the Company would hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1 st quarter 2018 financial results and business

BUENA, N.J. , May 01, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Deutsche Bank’s 43 rd Annual Health Care Conference . The Conference is taking place May 8-9, 2018 at the Intercontinental Hotel , Boston .

BUENA, N.J. , April 27, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) (“Teligent”) announced today that it has entered into separate, privately negotiated exchange agreements with certain holders of Teligent’s 3.75% Senior Convertible Notes due 2019 (the “2019 Notes”).  Pursuant to the

BUENA, N.J. , April 26, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1 st quarter 2018 financial results and business update.

BUENA, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

BUENA, N.J. , April 06, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

BUENA, N.J. , March 21, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

BUENA, N.J. , March 15, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2017 . Fourth Quarter 2017 Highlights Total revenues of $16.1 million

BUENA, N.J. , March 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Oppenheimer 28 th Annual Healthcare Conference. The Conference is taking place March 20-21, 2018 at the Westin Grand Central , New